Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools [Yahoo! Finance]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Yahoo! Finance
Therapeutics (NASDAQ:SYRE) , an estimated $25.78 million trade based on quarterly average pricing. VR Adviser, LLC added 1,000,000 shares of Spyre Therapeutics; the estimated trade size is $25.78 million (based on quarterly average pricing). The quarter-end value of the position increased by $75.73 million, reflecting both trading activity and share price appreciation. Spyre Therapeutics stake now represents 5.96% of VR Adviser's reportable AUM. The fund now holds 3,685,448 shares in Spyre Therapeutics, valued at $120.74 million as of December 31, 2025. Spyre Therapeutics remains a significant holding within a 27-position U.S. equity portfolio. What happened According to a U.S. Securities and Exchange Commission (SEC) filing dated February 17, 2026, VR Adviser, LLC increased its position in Spyre Therapeutics by 1,000,000 shares during the fourth quarter. The estimated transaction value is $25.78 million, calculated using the average closing price over the quarter. The q
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics (SYRE) had its price target raised by Stifel Nicolaus from $70.00 to $92.00. They now have a "buy" rating on the stock.MarketBeat
- Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms [Seeking Alpha]Seeking Alpha
- Spyre Therapeutics (SYRE) had its "buy" rating reaffirmed by BTIG Research. They now have a $70.00 price target on the stock.MarketBeat
- Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 [Yahoo! Finance]Yahoo! Finance
- Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026GlobeNewswire
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 3/5/26 - Form EFFECT
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- SYRE's page on the SEC website